Under Article 105 EPC, any third party may intervene in opposition proceedings after the opposition period has expired if it proves that proceedings for infringement of the same patent have been instituted against it. Intervention is in principle also possible during appeal proceedings (G 1/94, OJ EPO 1994, 787). The term "same patent" means that the infringement proceedings must be based on the European patent in suit in the opposition proceedings for which intervention is sought (see T 0338/89 of 10 December 1990, T 0446/95 of 23 March 1999).
Mr. Tsuji joined SFJ Pharmaceuticals in July of 2010 with over 25 years of clinical development experience across multiple therapeutic indications in the pharmaceutical industry. Mr. Tsuji was Head of Clinical Development at Schering-Plough KK, where he oversaw the Clinical Trials of hypercholesterolemia compound (Ezetimib) from Phase I studies through PMDA approval and malignant glioma compound (Temozolomide) from Phase II study through PMDA approval. Mr. Tsuji specializes in building development strategies for the approval of drugs. Mr. Tsuji has a Master’s Degree from Kanazawa University in Pharmaceutical Sciences.